However, it is still poorly understood whether combination therapy of DPP-4 inhibitors and SGLT2 inhibitors has more beneficial effects on β-cell mass and function compared to each medication and whether there are any different effects on pancreatic β-cells when these medications are administered between in an early phase and an advanced phase of diabetes. The gene discussed is DPP4; the disease is diabetes mellitus.